Technical Data
S1040-03E
SOCS 3 (Suppressor of Cytokine Signalling 3, Janus kinase (JAK) binding protein 3, STAT-induced STAT inhibitor 3, SSI 3)
Description:
SOCS3 specifically acts as a negative feedback regulator for the STAT3 pathways, by directly binding to the Tyr-759 motif of the IL-6 signal-transducing receptor subunit gp130, thereby preventing the IL-6 activation of STAT3. The expression of SOCS3 is inducible by numerous factors, including IL-6, IL-10, Toll-like receptor (TLR) agonists and IFN gamma, making this protein the focus of research into inflammatory diseases, such as Arthritis, Colitis, and Crohns Disease. SOCS3 expression has also been shown to affect IFN alpha sensitivity in tumor studies.

Applications:
Suitable for use in ELISA and Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 1:50-1:250, detects a band of ~30kD in Hela cell lysates.
Optimal dilution determined by the researcher.

Recommended Secondary Reagents:
I1904-65W: IgG, F(ab)2 (HRP) Pab RbxMo
I1904-66C: IgG, F(ab)2, X-Adsorbed (HRP) Pab RbxMo

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage, aliquot and store at -20C. Aliquots are stable for at least 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
MabIgG2b6A463Affinity Purified
SizeStorageShippingSourceHost
100ug4C (-20C Glycerol)Blue IceHumanMouse
Concentration:
~0.5mg/ml
Immunogen:
Full - length SOCS3 protein.
Purity:
Purified by protein A affinity chromatography.
Form
Supplied as a liquid in PBS, pH 7.4, 0.09% sodium azide before the addition of glycerol to 40%.
Specificity:
Recognizes suppressor of cytokine signaling 3 (SOCS3), a 30kDa member of the suppressor of cytokine signaling family (SOCS) which negatively regulate Janus Kinase (JAK) and signal transducer and activators of transcription (STAT) signaling pathways.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Lehmann, U. et al. (2003). SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J Biol. Chem. 278(1): 661-671 2. Suzuki, A. et al. (2001). CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J. Exp. Med. 193(4): 471-481 3. Lang, R. et al. (2003). SOCS3 regulates the plasticity of gp130 signaling. Nature Immunology 4(6): 546-550 4. Sakai, I. et al. (2002). Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood 100(8): 2926-2930 .